~~<i id='0670D60195'><strike id='0670D60195'><tt id='0670D60195'><pre id='0670D60195'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：Wikipedia 2025-09-06 10:34:47 Page View：1

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： NIH director takes cautious approach to Biden drug pricing priority
Next article： Medical records are filled with copy

focus

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

JPM 2024: Nvidia claims we're in biological revolution. Are we?

SipaviaAPImagesSANFRANCISCO—Thesmallhotelmeetingroomwaspackedlikearushhoursubway.Bankersindarksuitsw

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

How I ended up pumping milk in a bathroom stall at JPM 2024

AdobeSincehavingababy10monthsago,I’velearnedmanythings.Chiefamongthem:Pumpingsucks.Butskippingasessi